India · Delayed Price · Currency is INR Rossari Biotech Statistics
Total Valuation
Rossari Biotech has a market cap or net worth of INR 29.04 billion. The enterprise value is 32.25 billion.
| Market Cap | 29.04B |
| Enterprise Value | 32.25B |
Important Dates
The next confirmed earnings date is Saturday, July 18, 2026.
| Earnings Date | Jul 18, 2026 |
| Ex-Dividend Date | Jul 10, 2026 |
Share Statistics
Rossari Biotech has 55.39 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 55.39M |
| Shares Outstanding | 55.39M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 53.47% |
| Owned by Institutions (%) | 17.17% |
| Float | 17.65M |
Valuation Ratios
The trailing PE ratio is 19.47 and the forward PE ratio is 18.39. Rossari Biotech's PEG ratio is 1.48.
| PE Ratio | 19.47 |
| Forward PE | 18.39 |
| PS Ratio | 1.21 |
| PB Ratio | 2.18 |
| P/TBV Ratio | 2.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 44.62 |
| PEG Ratio | 1.48 |
Enterprise Valuation
| EV / Earnings | 21.61 |
| EV / Sales | 1.35 |
| EV / EBITDA | 11.90 |
| EV / EBIT | 16.81 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.57 |
| Quick Ratio | 0.85 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.62 |
| Debt / FCF | -2.18 |
| Interest Coverage | 6.66 |
Financial Efficiency
Return on equity (ROE) is 11.85% and return on invested capital (ROIC) is 8.80%.
| Return on Equity (ROE) | 11.85% |
| Return on Assets (ROA) | 5.67% |
| Return on Invested Capital (ROIC) | 8.80% |
| Return on Capital Employed (ROCE) | 12.67% |
| Weighted Average Cost of Capital (WACC) | 6.84% |
| Revenue Per Employee | 40.96M |
| Profits Per Employee | 2.55M |
| Employee Count | 585 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 4.42 |
Taxes
In the past 12 months, Rossari Biotech has paid 533.02 million in taxes.
| Income Tax | 533.02M |
| Effective Tax Rate | 26.32% |
Stock Price Statistics
The stock price has decreased by -25.51% in the last 52 weeks. The beta is 0.53, so Rossari Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.53 |
| 52-Week Price Change | -25.51% |
| 50-Day Moving Average | 519.04 |
| 200-Day Moving Average | 547.22 |
| Relative Strength Index (RSI) | 50.97 |
| Average Volume (20 Days) | 132,100 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rossari Biotech had revenue of INR 23.96 billion and earned 1.49 billion in profits. Earnings per share was 26.93.
| Revenue | 23.96B |
| Gross Profit | 7.19B |
| Operating Income | 1.90B |
| Pretax Income | 2.03B |
| Net Income | 1.49B |
| EBITDA | 2.60B |
| EBIT | 1.90B |
| Earnings Per Share (EPS) | 26.93 |
Balance Sheet
The company has 1.15 billion in cash and 4.36 billion in debt, with a net cash position of -3.21 billion or -57.97 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 4.36B |
| Net Cash | -3.21B |
| Net Cash Per Share | -57.97 |
| Equity (Book Value) | 13.33B |
| Book Value Per Share | 240.75 |
| Working Capital | 4.46B |
Cash Flow
In the last 12 months, operating cash flow was 650.68 million and capital expenditures -2.65 billion, giving a free cash flow of -2.00 billion.
| Operating Cash Flow | 650.68M |
| Capital Expenditures | -2.65B |
| Depreciation & Amortization | 703.02M |
| Net Borrowing | 2.13B |
| Free Cash Flow | -2.00B |
| FCF Per Share | -36.04 |
Margins
Gross margin is 30.00%, with operating and profit margins of 7.93% and 6.23%.
| Gross Margin | 30.00% |
| Operating Margin | 7.93% |
| Pretax Margin | 8.45% |
| Profit Margin | 6.23% |
| EBITDA Margin | 10.86% |
| EBIT Margin | 7.93% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.50, which amounts to a dividend yield of 0.10%.
| Dividend Per Share | 0.50 |
| Dividend Yield | 0.10% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 1.86% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 0.03% |
| Earnings Yield | 5.14% |
| FCF Yield | -6.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Rossari Biotech is 601.75, which is 14.62% higher than the current price. The consensus rating is "Buy".
| Price Target | 601.75 |
| Price Target Difference | 14.62% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Rossari Biotech has an Altman Z-Score of 4.21 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 4 |